Previous studies have shown that
N-hydroxy-N'-aminoguanidine (HAG) derivatives [RCH = NNHC(= NH)NHOH-tosylate] inhibit
ribonucleotide reductase activity and block the growth of
leukemia L1210 cells and human colon
carcinoma, HT-29, cells in culture. In the current studies, the role of the side chains and the location of the bond of the side chain moiety to HAG were investigated using a new series of HAG derivatives which contained as the R-group--cyclohexyl, phenyl-, pyridyl- or napthyl moieties. The effects of these compounds as inhibitors of L1210 cell growth and
ribonucleotide reductase activity were compared with the parent compound.
N-hydroxy-N'-aminoguanidine was less inhibitory to
ribonucleotide reductase activity and L1210 cell growth than
hydroxyurea. The phenyl-HAG compounds which included 1-benzyloxybenzylidene- and 4-cyclohexylmethoxybenzylidene-HAG inhibited
CDP reductase with IC50s which ranged from 50-110 microM. 1-Naphthylmethylene-HAG was more inhibitory than 2-naphthylmethylene-HAG and more inhibitory than the phenyl-HAG compounds. 2-Pyridylmethylene-HAG was more inhibitory than 3-pyridylmethylene- or 4-pyridylmethylene-HAG. While HAG inhibited
CDP and
ADP reductase activities essentially to the same extent, the HAG-derivatives inhibited
ADP reductase activity to a greater extent than
CDP reductase activity. Cyclohexylmethylene-HAG did not inhibit either L1210 cell growth or
ribonucleotide reductase activity. There was good correlation between the inhibition of
ribonucleotide reductase activity and L1210 cell growth by these HAG-derivatives. These data indicate that not only is the nature of the side chain substitution important, but also the location of the HAG-moiety on the ring position.